MAPT and tauopathy: Because K280 is critical for acetylation-induced tauopathy (Figure 1) and therapeutic potential of targeting acK280 was observed in vivo in tau-P301L mice (Supplemental Figures 13 and 14), we developed a monoclonal antibody, Y01, that is specific for tau-acK280 and characterized this reagent for use in subsequent analyses.